Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer

To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC). This study was a prospective, multicenter, one-arm, open-label, phase II trial. Patients with unresectable PC, who showed disease progression du...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	World journal of gastrointestinal oncology 2018-12, Vol.10 (12), p.505-515
Hauptverfasser:	Chung, Moon Jae, Kang, Huapyong, Kim, Ho Gak, Hyun, Jong Jin, Lee, Jun Kyu, Lee, Kwang Hyuck, Noh, Myung Hwan, Kang, Dae Hwan, Lee, Sang Hyub, Bang, Seungmin
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical Trials Study
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!